TrialSignal
Clinical trial intelligence report
Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01572545
Status
COMPLETED
Phase
NA
Sponsor
Aristotle University Of Thessaloniki
Executive brief
Investment-Ready Snapshot
This completed clinical trial compared the effects of Zoledronic Acid and Denosumab on serum sclerostin levels, a key biomarker in bone metabolism, in postmenopausal women with low bone mass. The study aimed to provide insights into the efficacy of these two leading osteoporosis treatments.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01572545
Indication
Postmenopausal Osteoporosis
Modality
monoclonal antibody
Target
Serum sclerostin levels in postmenopausal women with low bone mass
Intervention
Denosumab, Zoledronic acid
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.